Search Type: drug or dietary supplement name
Search Term: leflunomide (ARAVA)


Worst Pills, Best Pills Newsletter Articles | Health Letter Articles

Worst Pills, Best Pills Newsletter Articles

Search results below include Worst Pills, Best Pills Newsletter Articles where your selected drug is a secondary subject of discussion
  • Drug Interactions: Warfarin (COUMADIN) [hide all summaries]
    (December 2007)
    This article explains how to understand the International Normalized Ratio (INR), a test applied to a sample of a patient’s blood to determine how “thin” it is when you are using the blood thinner COUMADIN (warfarin). In addition, the article lists more than 50 drugs or dietary supplements that can interact harmfully with COUMADIN to cause the blood to be too thin (abnormal bleeding) or not thin enough which could result in lessening the effect of COUMADIN in stopping blood clot formation.
  • New Research Results on Safety of Newly Approved Drugs Causes Health Research Group to Extend Five-Year Waiting Rule to Seven Years [hide all summaries]
    (June 2002)
    A study published in the May 1, 2002 Journal of the American Medical Association (JAMA) has resulted in a major change in the Health Research Group’s drug safety policy. The study, in association with physicians from the Harvard Medical School, examined the frequency and timing of the identification of new adverse drug reactions resulting in the addition of a black box warning in the drug’s professional product labeling or its outright removal from the market. You should wait at least seven years from the date of release to take any new drug unless it is one of those rare “therapeutic advances” that offers you a documented therapeutic advantage over older, proven drugs.

Health Letter Articles

Search results below include Health Letter Articles where your selected drug is a secondary subject of discussion
  • Outrage: New Study: Wait Seven Years to Use New Drugs [hide all summaries]
    (June 2002)
    A study published in the May 1, 2002 Journal of the American Medical Association (JAMA) has resulted in a major change in the Health Research Group's drug safety policy. The study, in association with physicians from the Harvard Medical School, examined the frequency and timing of the identification of new adverse drug reactions resulting in the addition of a black box warning in the drug's professional product labeling or its outright removal from the market. Three of the authors have close identification with the Health Research Group: its director, Sidney M. Wolfe, and former HRG staffers Drs. Steffi Woolhandler and David Himmelstein. The other co-authors are affiliated with the Harvard Medical School.

SHOW primary search results for leflunomide (ARAVA)

Copyright © 2017 Public Citizen's Health Research Group. All rights reserved. https://www.worstpills.org/